Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely ...
Safeguards Of Dapagliflozin's Half Billion USD Sales In China: Astrazeneca. Legal News and Analysis - China - Conventus Law ...
CHICAGO, IL—High-risk older patients with a history of heart failure (HF) who are undergoing transcatheter aortic valve implantation have better outcomes when taking dapagliflozin, results from the ...
"Dapagliflozin reduced UACR compared with placebo, although considerable variability was observed among individuals. These variations, which were consistent after re-exposure, underscore the need ...
The kind of, molecule, the API when we export is being ... On the market impact as well as influence of Dapagliflozin generics, Juneja told Financial Express.com: “…those patients who are ...